Spath Paolo, Maioli Filippo, Campana Federica, Gabellini Teresa, Perulli Annalisa, Leone Michele, Giacchi Francesco, Di Iasio Giacomo, Marini Massimiliano, Massini Silvia, Pomatto Sara, Angherà Cecilia, Tarantini Salvatore
Vascular Surgery Unit, Hospital "Infermi" Rimini, Rimini, Italy.
Vascular Surgery, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
J Endovasc Ther. 2024 Jul 31:15266028241266182. doi: 10.1177/15266028241266182.
This single-center study aimed to assess patients who underwent intentional percutaneous endovascular aortic aneurysm repair (pEVAR) with Hybrid Technique combining a single Perclose (Abbott, Abbott Park, Illinois) Suture-Mediated Closure Device + single Angio-Seal VIP 8F (Terumo, Tokyo, Japan) and compare outcomes with the standard Dual Perclose technique. Materials and Methods: Consecutive elective pEVAR patients treated from November 2022 to November 2023, with healthy femoral accesses and introducer sheaths ≤20 French (F) outer diameter, were included. Coin-toss randomization determined whether a combination of single Perclose Device + single Angio-Seal VIP 8F (Hybrid Technique) or the standard double Perclose Devices (Dual Perclose) was used. In Hybrid Technique, a single Perclose device was positioned at 12 o'clock; a single Angio-Seal VIP 8F was placed after sheaths removal. Dual Perclose followed standard procedure. Primary endpoints included immediate hemostasis, sheath diameter differences, access conversion rate, technical success, and cost analysis.
The study involved 60 pEVAR patients (median age=78, interquartile range [IQR]=72-85 years) within the inclusion criteria. In 14 (24%) cases, only 1 femoral access was studied. There were 106 pEVAR accesses, with 58 (54.7%) in the Hybrid Technique group and 48 (45.3%) in the Dual Perclose group. Both groups exhibited homogeneity in pre-operative characteristics and sheath diameter (Hybrid Technique-16F vs Dual Perclose-18F; p=0.202). Immediate hemostasis was achieved in 100% of the Hybrid Technique group vs 87.5% for the Dual Perclose group (p=0.006). Surgical access conversion was unnecessary. Technical success was 100%, with all 6 femoral bleeding cases after Dual Perclose resolved endovascularly, using additional devices. Cost analysis showed a median cost of 330 euros (IQR=0) for the Hybrid Technique group vs 384 euros (IQR=360-456) for the Dual Perclose group (p<0.001). Thirty-day mortality was 3%, in 2 fragile patients, without access-related complications. Multivariate analysis identified Dual Perclose access (odds ratio [OR]=35.6; 95% confidence interval [CI]=18.3-36.8; p<0.001) and obesity (OR=19.7; 95% CI=1.4-23.9.5; p<0.001) as independent risk factors for immediate hemostasis failure. Median follow-up was 134 days (IQR=41-227), with 1 Hybrid Technique case (2%) successfully treated with thrombin injection for a small femoral pseudoaneurysm after 62 days.
The elective Hybrid Technique with combination of single Perclose Device + single Angio-Seal VIP 8F during pEVAR in selected patients appears to be non-inferior to the standard Dual Perclose procedure. It demonstrates a positive trend in reducing immediate hemostasis failure and costs. Both procedures achieved technical success and avoiding surgical access conversions.
This study introduces a novel elective hybrid technique combining a single Perclose device with a single Angio-Seal VIP 8Fr for percutaneous endovascular abdominal aortic interventions. Results for hybrid technique showed 100% technical success and efficient immediate hemostasis, while costing less than standard dual Perclose procedure. Both procedures did not require surgical conversions. Despite being a single-center study, it demonstrates potential benefits of the intentional application of this hybrid technique towards minimally invasiveness. Obesity and dual Perclose technique were identified as independent risk factors for hemostasis failure, reaffirming the hybrid technique procedure's efficacy as well as and non-inferiority to standard procedure.
本单中心研究旨在评估采用单一Perclose(雅培公司,伊利诺伊州雅培公园)缝合介导闭合装置+单一Angio-Seal VIP 8F(日本东京泰尔茂公司)的混合技术进行经皮血管腔内主动脉瘤修复术(pEVAR)的患者,并将结果与标准双Perclose技术进行比较。材料与方法:纳入2022年11月至2023年11月接受连续择期pEVAR治疗、股动脉入路健康且导入鞘外径≤20F的患者。通过抛硬币随机化确定使用单一Perclose装置+单一Angio-Seal VIP 8F的组合(混合技术)还是标准双Perclose装置(双Perclose)。在混合技术中,将单一Perclose装置置于12点位置;移除鞘管后放置单一Angio-Seal VIP 8F。双Perclose遵循标准程序。主要终点包括即时止血、鞘管直径差异、入路转换率、技术成功率和成本分析。
该研究纳入了60例符合纳入标准的pEVAR患者(中位年龄=78岁,四分位间距[IQR]=72 - 85岁)。在14例(24%)病例中,仅研究了1个股动脉入路。共有106个pEVAR入路,混合技术组58个(54.7%),双Perclose组48个(45.3%)。两组在术前特征和鞘管直径方面具有同质性(混合技术组-16F vs双Perclose组-18F;p = 0.202)。混合技术组100%实现即时止血,双Perclose组为87.5%(p = 0.006)。无需进行手术入路转换。技术成功率为100%,双Perclose术后的6例股动脉出血病例均通过血管腔内使用额外装置得以解决。成本分析显示,混合技术组的中位成本为330欧元(IQR = 0),双Perclose组为384欧元(IQR = 360 - 456)(p < 0.001)。30天死亡率为3%,发生在2例体弱患者中,无入路相关并发症。多因素分析确定双Perclose入路(比值比[OR]=35.6;95%置信区间[CI]=18.3 - 36.8;p < 0.001)和肥胖(OR = 19.7;95% CI = 1.4 - 23.95;p < 0.001)是即时止血失败的独立危险因素。中位随访时间为134天(IQR = 41 - 227),1例混合技术病例(2%)在62天后因小股动脉假性动脉瘤成功接受凝血酶注射治疗。
在选定患者的pEVAR过程中,采用单一Perclose装置+单一Angio-Seal VIP 8F的择期混合技术似乎不劣于标准双Perclose程序。它在减少即时止血失败和成本方面呈现出积极趋势。两种程序均实现了技术成功并避免了手术入路转换。
本研究引入了一种新型的择期混合技术,将单一Perclose装置与单一Angio-Seal VIP 8Fr用于经皮血管腔内腹主动脉干预。混合技术的结果显示技术成功率为100%且即时止血有效,同时成本低于标准双Perclose程序。两种程序均无需手术转换。尽管是单中心研究,但它证明了有意应用这种混合技术实现微创性的潜在益处。肥胖和双Perclose技术被确定为止血失败的独立危险因素,再次证实了混合技术程序的有效性以及不劣于标准程序。